ArticleDiabetes, metabolic syndrome and obesity : targets and therapy2026
Vitamin D Deficiency, Inflammatory Biomarkers, and MASLD in Older Adults with Type 2 Diabetes: A Cross-Sectional Study.
Article in Diabetes, metabolic syndrome and obesity : targets and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: This study aimed to investigate the association between serum 25-hydroxyvitamin D (25[OH]D) levels and metabolic dysfunction-associated steatotic liver disease (MASLD) in older patients with type 2 diabetes mellitus. Patients and Methods: This retrospective cross-sectional study included 1044 older patients with T2DM who were treated at the Department of Endocrinology of Gansu Provincial Hospital between April 2021 and June 2024. MASLD was diagnosed by abdominal ultrasonography. Demographic, metabolic, and biochemical data were collected, including high-sensitivity C-reactive protein (hs-CRP), sialic acid (SA), and homocysteine (HCY). Binary logistic regression analysis was performed to assess the independent association between 25(OH)D levels and the presence of MASLD. Results: MASLD was present in 64.0% of participants. Serum 25(OH)D levels were significantly lower in the MASLD group than in the non-MASLD group. After adjusting for age, sex, diabetes duration, body mass index, glycemic parameters, lipid profiles, and inflammatory markers, each 1 ng/mL decrease in 25(OH)D level was associated with 27.6% higher odds of MASLD (odds ratio [OR] = 0.724, 95% confidence interval [CI]: 0.686-0.765, P < 0.001). Receiver operating characteristic (ROC) analysis demonstrated the discriminatory performance of 25(OH)D for MASLD, yielding an area under the curve of 0.856 (95% CI: 0.828-0.884, P < 0.001) and an optimal cutoff value of 19.95 ng/mL. Conclusion: Low serum 25(OH)D levels were independently associated with higher odds of MASLD in older patients with T2DM. Vitamin D status may have potential value for MASLD risk stratification, but prospective studies are required before treatment recommendations can be made.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.